Amid socialdistancing and other measures to help reduce the spread ofcoronavirus, digital therapeutics have come into sharper focus.(Image: Shutterstock)
Digital therapeutics are enjoying renewed attention amid thecoronavirus crisis, and new industry analyses assert that healthbenefits managers and advisers might consider these prescriptionsoftware alternatives as the cost of health care rises.
"Digital therapeutics are poised to change health care byallowing for the diagnosis, management, and treatment of medicalconditions in a low-cost, scalable way," the Boston-based techadvisory firm Lux Research said in a new analysis. "All health carestakeholders will be impacted by the adoption of thistechnology."
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Mike Scarcella
Mike Scarcella is a senior editor in Washington on ALM Media's regulatory desk. Contact him at [email protected]. On Twitter: @MikeScarcella. Mike works on a slate of newsletters: Supreme Court Brief | Higher Law | Compliance Hot Spots | Labor of Law.
